Population pharmacokinetic‐pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 11, 2015-11 ,pp. : 1236-1247

John Wiley & Sons Inc

Access to resources Recommend Favorite

The novel cardiac myosin activator omecamtiv mecarbil increases the calcium sensitivity of force production in isolated cardiomyocytes and skeletal muscle fibres of the rat

By  

BRITISH JOURNAL OF PHARMACOLOGY (ELECTRONIC), Vol. 172, Iss. 18, 2015-09 ,pp. : 4506-4518

John Wiley & Sons Inc

Access to resources Recommend Favorite

Reversal of opioid‐induced respiratory depression by BK‐channel blocker GAL021: A pharmacokinetic‐pharmacodynamic modeling study in healthy volunteers

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 97, Iss. 6, 2015-06 ,pp. : 641-649

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pharmacokinetic–pharmacodynamic modelling of intravenous and oral topiramate and its effect on phonemic fluency in adult healthy volunteers

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 79, Iss. 5, 2015-05 ,pp. : 820-830

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pharmacokinetic/pharmacodynamic modelling of cardiac toxicity in venlafaxine overdose

By Mégarbane Bruno   Bloch Vanessa   Deye Nicolas   Baud Frédéric  

Intensive Care Medicine, Vol. 33, Iss. 1, 2007-01 ,pp. : 195-196

Springer Publishing Company

Access to resources Recommend Favorite